SCHEDULE 13G: Alyeska Investment Group Discloses 9.99% Passive Stake in Marker Therapeutics, Inc.

Alyeska Investment Group, L.P., along with its affiliates, has disclosed a passive beneficial ownership of 9.99% in Marker Therapeutics, Inc., totaling 1,069,659 shares as of December 31, 2024.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 1,069,659 shares of Marker Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the outstanding Common Stock of Marker Therapeutics, Inc.
• The reported stake includes 332,550 shares of Common Stock and warrants to purchase up to 737,109 additional shares, which are limited by a 9.99% exercise cap.
• The filing is a Schedule 13G, indicating a passive investment, meaning the shares were not acquired for the purpose of changing or influencing the control of the issuer.
• The percentage calculation is based on 10,707,295 outstanding shares of Common Stock, as reported in Marker Therapeutics' Form 10-Q filed with the SEC on November 14, 2024.

Sentiment

Score: 5

Explanation: Neutral. This is a standard regulatory filing disclosing a passive ownership stake, providing factual information without indicating positive or negative operational performance or strategic shifts for the issuer.

Positives

• The disclosure indicates significant institutional interest in Marker Therapeutics, Inc. from Alyeska Investment Group, L.P. and its affiliates.
• The filing confirms that the investment is passive, suggesting no immediate intent to disrupt current management or operations.

Negatives

• This filing is a routine ownership disclosure and does not contain information regarding negative operational or financial performance of Marker Therapeutics, Inc.

Risks

• The document does not explicitly mention specific risks related to Marker Therapeutics, Inc.'s operations or financial health.
• The passive nature of the investment means the reporting persons are not seeking to influence or change the control of the issuer, which could be seen as a lack of active oversight from a significant shareholder.

Future Outlook

This document is a regulatory disclosure of ownership and does not contain any forward-looking statements or guidance from Marker Therapeutics, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Marker Therapeutics, Inc.

Industry Context

This filing is a routine disclosure of a passive investment by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this ownership disclosure.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or the nature of their investment.

Key Dates

Keywords

Marker Therapeutics, Alyeska Investment Group, Schedule 13G, beneficial ownership, Common Stock, institutional investment, passive stake, SEC filing